Addex wins EuropaBio’s European Biotech SME Award


Geneva/Brussels – Swiss biotech company Addex Pharmaceuticals S.A. is the first winner of EuropaBio’s new ”Most Innovative European Biotech SME Award”. On occasion of EuropaBio’s event on Innovation in Biotechnology in Brussels, the developer of small molecule allosteric modulators , which out-competed 31 other biotech companies including AMSilk, KeyGene, Prosensa, and TiGenix, received a EUR10,000 cheque and two years free membership of EuropaBio. “Addex has pioneered an extremely innovative solution to address important therapeutic areas such as Parkinson’s disease, schizophrenia, Alzheimer’s disease, endometriosis and benign prostatic hyperplasia,” said EuropaBio Chairman, Andrea Rappagliosi. “We look forward to bringing allosteric modulators to patients as medical therapies, starting with our lead products for Parkinson’s disease and schizophrenia which will enter phase II clinical trial testing in the next few weeks,” added Addex’s CEO Vincent Mutel. The Geneva-based company, which went public in 2007 and raised a total amount of CHF263m since it was founded in 2002, currently has two candidates entering clinical phase II next year that open up allosteric modulation of metabotrophic glutamate receptors (mGluR). Addex’s schizophrenia programme ADX71149, which is partnered with Ortho-McNeil-Janssen, a Johnson & Johnson subsidiary, upregulates expression of mGluR2. ADX48621, a structurally new negative mGluR5 modulator that was developed after termination of Addex’ ADX100059 programme, is being developed in Levodopa-induced dyskenesia, a severe adverse effect in patients with Parkinson’s disease. The Phase II trial is currently unpartnered but partially funded (US$900,000 a quarter of the trial’s cost) by the Michael J. Fox foundation. Addex is financed until early 2013 at a burn rate of CHF30m annually. Additionally, Merck & Co. is developing preclinical positive mGluR5 modulator ADX633365 (schizophrenia) and a mGluR4 booster for Parkinson’s disease discovered by Addex. “Our allosteric modulators deliver all advantages of small drugs while offering high target specificity and a new mode of action. In contrast to small drugs or biologicals they do not act as on/off-switches at their targets but more like a dimmer switch, which offers greater physiological modulation” Mutel explained to EuroBiotechNews. According to Addex’s CEO, the development of a novel discovery and bio-assay platform for allosteric modulators together with an allostery-biased chemical library of 70,000 compounds makes Addex a biopharmaceutical firm.



Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...



London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...



Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...



After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...



The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...



Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...



Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....



Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2015 BIOCOM



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • HYBRIGENICS (F)1.79 EUR20.13%
  • PROTHENA PLC (IE)39.44 USD14.32%
  • CELLECTIS (F)40.90 EUR11.29%


  • ANTISOMA (UK)1.00 GBP-35.48%
  • BIONOR PHARMA (N)2.19 NOK-6.01%


  • GALAPAGOS (B)52.35 EUR39.3%
  • HYBRIGENICS (F)1.79 EUR38.8%
  • CELLECTIS (F)40.90 EUR37.1%


  • CYTOS (CH)0.64 CHF-36.6%
  • ANTISOMA (UK)1.00 GBP-35.5%
  • MEDIGENE (D)8.30 EUR-24.3%


  • CELLECTIS (F)40.90 EUR558.6%
  • WILEX (D)4.28 EUR463.2%
  • ADOCIA (F)69.50 EUR436.7%


  • CHRONTECH PHARMA (S)0.01 SEK-90.9%
  • THROMBOGENICS (B)5.34 EUR-70.1%
  • ACTIVE BIOTECH (S)10.60 SEK-68.8%

No liability assumed, Date: 01.06.2015

Current issue

All issues